WO2008111466A1 - 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法 - Google Patents

遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法 Download PDF

Info

Publication number
WO2008111466A1
WO2008111466A1 PCT/JP2008/053981 JP2008053981W WO2008111466A1 WO 2008111466 A1 WO2008111466 A1 WO 2008111466A1 JP 2008053981 W JP2008053981 W JP 2008053981W WO 2008111466 A1 WO2008111466 A1 WO 2008111466A1
Authority
WO
WIPO (PCT)
Prior art keywords
examination
activity
gene
measure
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053981
Other languages
English (en)
French (fr)
Inventor
Yoshiharu Mizui
Naoko Hata
Masao Iwata
Rie Sugano
Naoki Toritsuka
Taku Yoshida
Mai Uesugi
Tadashi Kadowaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to EP08721401A priority Critical patent/EP2131193A4/en
Priority to US12/529,971 priority patent/US20100086931A1/en
Priority to JP2009503998A priority patent/JPWO2008111466A1/ja
Publication of WO2008111466A1 publication Critical patent/WO2008111466A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　本発明は、プラジエノライド誘導体の生体への作用を検定するための方法、プローブ、プライマー、抗体、試薬、およびキットの提供をその目的とする。本発明によれば、遺伝子の発現量減少を指標とする、プラジエノライド誘導体の作用検定方法が提供される。
PCT/JP2008/053981 2007-03-05 2008-03-05 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法 Ceased WO2008111466A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08721401A EP2131193A4 (en) 2007-03-05 2008-03-05 METHOD FOR THE INVESTIGATION OF THE ACTIVITY OF ANTICROBIAL AGENT USING A REDUCTION OF GENE EXPRESSION LEVELS AS MEASURE
US12/529,971 US20100086931A1 (en) 2007-03-05 2008-03-05 Method for assaying action of antitumor agent using decrease in gene expression level as index
JP2009503998A JPWO2008111466A1 (ja) 2007-03-05 2008-03-05 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90477507P 2007-03-05 2007-03-05
US60/904,775 2007-03-05
US96048607P 2007-10-01 2007-10-01
US60/960,486 2007-10-01

Publications (1)

Publication Number Publication Date
WO2008111466A1 true WO2008111466A1 (ja) 2008-09-18

Family

ID=39759409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053981 Ceased WO2008111466A1 (ja) 2007-03-05 2008-03-05 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法

Country Status (4)

Country Link
US (1) US20100086931A1 (ja)
EP (1) EP2131193A4 (ja)
JP (1) JPWO2008111466A1 (ja)
WO (1) WO2008111466A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521176A (ja) * 2018-04-12 2021-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500684A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性アミノ酸連鎖の決定方法
WO2000028082A1 (fr) 1998-11-09 2000-05-18 Eiken Kagaku Kabushiki Kaisha Procede de synthese d'acide nucleique
JP2000512495A (ja) * 1996-06-13 2000-09-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 迅速に増殖している細胞中のｄｎａ複製に干渉する癌治療用の化合物及びこのような化合物のスクリーニング方法
WO2002060890A1 (en) 2001-02-01 2002-08-08 Mercian Corporation Novel physiologically active substances
WO2003099813A1 (en) 2002-05-29 2003-12-04 Mercian Corporation Novel physiolgically active substances
JP2006006231A (ja) * 2004-06-28 2006-01-12 Japan Health Science Foundation 肥満に関連するシステインジオキシゲナーゼ（ｃｄｏ）発現調節因子のスクリーニング方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075681A1 (ja) * 2004-02-06 2005-08-18 Eisai R & D Management Co., Ltd. 抗癌剤に対する癌細胞の感受性を検定する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500684A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性アミノ酸連鎖の決定方法
JP2000512495A (ja) * 1996-06-13 2000-09-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 迅速に増殖している細胞中のｄｎａ複製に干渉する癌治療用の化合物及びこのような化合物のスクリーニング方法
WO2000028082A1 (fr) 1998-11-09 2000-05-18 Eiken Kagaku Kabushiki Kaisha Procede de synthese d'acide nucleique
WO2002060890A1 (en) 2001-02-01 2002-08-08 Mercian Corporation Novel physiologically active substances
WO2003099813A1 (en) 2002-05-29 2003-12-04 Mercian Corporation Novel physiolgically active substances
JP2006006231A (ja) * 2004-06-28 2006-01-12 Japan Health Science Foundation 肥満に関連するシステインジオキシゲナーゼ（ｃｄｏ）発現調節因子のスクリーニング方法

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
"Molecular Cloning, A Laboratory Manual 2nd ed", 1989, COLD SPRING HARBOR PRESS
"Molecular Cloning, A Laboratory Manual 2nd ed.", 1989, COLD SPRING HARBOR PRESS
"Molecular Cloning, A Laboratory Manual 3d ed", 2001, COLD SPRING HARBOR PRESS
ANAL.BIOCHEM., vol. 151, 1985, pages 540 - 6
CAMPA, M.J. ET AL., CANCER RES., vol. 63, 2003, pages 1652 - 1656
CHOU-FASMAN, ANN.REV.BIOCHEM., vol. 47, 1978, pages 251 - 76
DALBADIE-MCFARLAND ET AL., PROC.NATL.ACAD.SCI. USA, vol. 79, 1982, pages 6409 - 13
HASHIMOTO-GOTO ET AL., GENE, vol. 152, 1995, pages 271 - 5
KINKEL, PROC.NATL.ACAD.SCI.USA, vol. 82, 1985, pages 488 - 92
KRAMER; FRITZ, METHOD.ENZYMOL., vol. 154, 1987, pages 350 - 67
KUNKEL, METHOD. ENZYMOL., vol. 85, 1988, pages 2763 - 6
KYTE-DOOLITTLE, J.MOL.BIOL., vol. 157, 1982, pages 105 - 22
MARK ET AL., PROC.NATL.ACAD.SCI.USA, vol. 81, 1984, pages 5662 - 6
METH. ENZYM., vol. 164, 1988, pages 765
MIZUI ET AL., J. ANTIBIOTICS, vol. 577, 2004, pages 188 - 196
NATURE, vol. 256, 1975, pages 495
SAKAI T.: "Biseibutusu Shigen Karano Shinki Koshuyo Kassei Busshitsu no Tansaku", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 126, no. SUPPL. 5, 2006, pages 32 - 33 *
See also references of EP2131193A4 *
WANG ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3
ZOLLER; SMITH, NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521176A (ja) * 2018-04-12 2021-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP7334181B2 (ja) 2018-04-12 2023-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP2023175691A (ja) * 2018-04-12 2023-12-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体
JP7676484B2 (ja) 2018-04-12 2025-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体

Also Published As

Publication number Publication date
US20100086931A1 (en) 2010-04-08
JPWO2008111466A1 (ja) 2010-06-24
EP2131193A4 (en) 2010-10-20
EP2131193A1 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2010091049A3 (en) Diagnosis and treatment of cancer
EP1972269B8 (de) System zur in-vivo Messung einer Analytkonzentration
EP2989981B8 (en) Multi-site body fluid sampling and analysis cartridge
WO2007123791A3 (en) Methods of determining cellular chemosensitivity
BRPI1006215A2 (pt) " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
WO2010041892A3 (ko) Aimp1 폴리펩티드의 신규한 용도
WO2007087261A3 (en) Rapid test apparatus
WO2012021407A3 (en) Biomarkers for stroke
WO2009129505A3 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
WO2007098444A3 (en) Methods for analysis of extracellular rna species
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
EP2021794B8 (en) Use of protein s100a 12 as a marker for colorectal cancer
EP2522743A3 (en) Genetic variants contributing to risk of prostate cancer
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2011074802A3 (ko) 전립선암 진단용 키트 및 진단방법
WO2007008864A3 (en) Wireless cmos biosensor
WO2009100447A3 (en) Detection of degradative enzymes and biomolecules in bodily fluids
WO2009122444A3 (en) Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof
WO2008111466A1 (ja) 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
WO2008090177A3 (en) Diagnosis of prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721401

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009503998

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008721401

Country of ref document: EP